Background {#Sec1}
==========

In many organisms, highly conserved Na^+^/K^+^ ATPases are responsible for maintaining ion gradients across the plasma membrane through ATP-dependent asymmetric translocation of Na^+^ and K^+^ ions. These ion gradients maintain the resting potential of cells, which facilitates neural signaling and many essential secondary processes. Mature Na^+^/K^+^ ATPase complexes are heteromultimers of alpha, beta, and gamma subunits in mammals. Flies express only the alpha and beta subunits, the former of which is known as ATPalpha. Like its mammalian homologue, ATPalpha contains ten transmembrane domains and has the ATP-dependent catalytic activity essential for pump function \[[@CR1]-[@CR3]\].

Mutations affecting the alpha subunit of the Na^+^/K^+^ ATPase in humans are associated with at least three human diseases: Rapid-onset Dystonia Parkinsonism (RDP), Familial Hemiplegic Migraine (FHM), and Alternating Hemiplegia of Childhood (AHC; \[[@CR4]\]). RDP is a severe DOPA non-responsive form of dystonia the etiology of which is poorly understood \[[@CR5]\]. FHM, possibly the most severe form of migraine, is associated with a debilitating partial paralysis, and currently is largely untreatable \[[@CR6]\]. AHC is a severe childhood locomotor disease associated with recurring acute bouts of paralysis and muscle weakness, and general developmental delays (reviewed by \[[@CR7]\]). Recently Sasaki and colleagues have described several children who seem to have a disease intermediate to AHC and RDP \[[@CR8]\]. All of these diseases are complex neuromuscular conditions associated with marked locomotor dysfunction and for which the underlying pathogenesis is poorly understood.

*Drosophila* conditional mutants have been isolated based upon temperature-sensitive (TS) or bang-sensitive (BS) paralysis phenotypes over the past many decades. TS mutants generally become paralyzed in less than five minutes at 38°C and BS mutants paralyze in response to 20 seconds of mechanical stress. These classes of mutants have proven informative and have defined many essential components of neural signaling \[[@CR9]-[@CR15]\]. Conditional TS mutations typically affect critical neural proteins and include well-studied genes such as *para* (voltage-dependent NaCH), *NapTS* (RNA helicase affecting *para* transcripts), *cacophony* (a voltage-gated calcium channel), *ATPalpha* (Na^+^/K^+^ ATPase), *comatose* (dNSF1), *shibire* (Dynamin), *syntaxin*, *synaptobrevin*, and *dao* (regulator of Erg-type K-channels), to name a few \[[@CR15]-[@CR24]\]. Conditional BS mutations can also affect important neural signaling and ion homeostasis proteins, such as para and ATPalpha \[[@CR23],[@CR25]\]. They also affect many proteins with integral roles in bioenergetics and mitochondrial function, such as sesB, ATP6, kdn, eas, and SOD2 \[[@CR26]-[@CR30]\]. Interestingly, numerous BS mutants have been shown to exhibit seizures and model epilepsies (e.g. *para*^*BSS1*^*, ATP6*^*1*^, and *Kazachoc*; \[[@CR25],[@CR31],[@CR32]\]). BS and TS conditional mutants have proven incredibly important to our understanding of neurobiology and previous studies have successfully used them to identify genes that modify these behaviors (e.g. \[[@CR33]-[@CR35]\]). However, there are no reports of genome-wide screens for modifier loci using these behavioral phenotypes in *Drosophila* or studying *ATPalpha* in any model system. This suggests that such an approach could yield novel loci involved in regulating ion homeostasis or neural excitability.

It has previously been shown that mutations in *ATPalpha* result in profound neural and locomotor dysfunction in *Drosophila* \[[@CR23],[@CR36]-[@CR40]\]. Hypomorphic *ATPalpha* alleles, such as *ATPalpha*^*2206*^, display BS paralysis and phenocopy injection of the selective Na^+^/K^+^ ATPase inhibitor, ouabain \[[@CR39]\]. The *ATPalpha*^*DTS1*^ mutation is a dominant, conditional, gain-of-function, missense mutation \[[@CR23]\]. The mutation results in an E982K substitution near the protein's C-terminus (short isoform numbering). *ATPalpha*^*DTS1*^ heterozygotes exhibit rapid paralysis at 38°C with complete penetrance. This is thought to be a result of conditional neuronal hyperexcitability caused by the mutation \[[@CR23]\]. *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^ are also dominant missense mutations affecting evolutionarily conserved amino acids \[[@CR36]\]. However, they each exhibit unique locomotor phenotypes. *ATPalpha*^*CJ5*^ behaves like a loss-of-function allele of *ATPalpha*, exhibiting haploinsufficiency and BS paralysis \[[@CR36]\]. *ATPalpha*^*CJ10*^ exhibits BS and progressive TS phenotypes, suggesting this is a loss-of-function allele that exhibits weak gain-of-function features, which are uncovered with age \[[@CR36]\]. Thus, *ATPalpha*^*DTS1*^, *ATPalpha*^*CJ5*^, and *ATPalpha*^*CJ10*^ are all dominant, phenotypically well-characterized, and possibly functionally distinct, conditional locomotor mutants. Such alleles are ideally suited for a modifier screen. Using multiple alleles of *ATPalpha* increases the power of the screen and affords the likelihood of identifying allele-specific modifiers. Furthermore, to our knowledge, this is the first report of a genome wide genetic screen in any animal system using three distinct alleles of the same gene in parallel to identify allele-specific interactions.

Deficiency screens have been effectively used for elucidating novel gene interactions in *Drosophila* using various phenotypes \[[@CR41]-[@CR43]\]. Deficiency (*Df*) strains each have a unique deletion of a segment of the genome. Phenotypically screening for genetic interactions between defined point mutations and an individual defined deficiency is an efficient way to identify modifier loci. Using a collection of *Dfs* covering a high percentage of the genome (95-98%), one can identify critical modifier loci anywhere in the genome. This provides an efficient yet powerful and unbiased forward genetic approach. Critical loci can often be narrowed to single genes using smaller deficiencies and single gene disruptions. We have performed such a screen using *ATPalpha*^*DTS1*^, *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^, identified 64 critical modifier intervals, and successfully confirmed 50 single-gene modifiers, including numerous novel loci of interest. These data suggest the existence of many susceptibility loci capable of modifying migraine, locomotor and seizure dysfunction in animals and provide a rich data set from which new targets for anti-migraine or anti-epileptic drugs could be drawn.

Results {#Sec2}
=======

Primary genetic modifier screen {#Sec3}
-------------------------------

To identify new genes that interact with *ATPalpha* we performed a deficiency screen using three characterized alleles: *ATPalpha*^*DTS1*^, *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^. We used the Bloomington Stock Center deficiency (*Df*) kit that covers approximately 98% of the *Drosophila* genome. All of the 467 *Df* strains we received were tested with at least one *ATPalpha* mutant allele and the vast majority of strains were tested with multiple alleles (see Table [1](#Tab1){ref-type="table"}). Each of the three *ATPalpha* mutants was mated to each *Df* line. F~1~ progeny bearing *ATPalpha*^*DTS1*^ and each deficiency were subjected to TS assays while progeny bearing *ATPalpha*^*CJ5*^ or *ATPalpha*^*CJ10*^ and each *Df* were assayed for BS. The average response for *ATPalpha*^*DTS1*^*, ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^*Df* double mutants was 34.8+/−25.3, 89.9+/−53.6 and 41.5+/−34.8 seconds, respectively (Additional file [1](#MOESM1){ref-type="media"}). We used these values to identify putative genetic interactions. *Df(3R)BSC819* contains a deletion of the *ATPalpha* locus and failed to complement each mutant allele, as expected.Table 1**Primary screen summary*DTS1**CJ5**CJ10*Number tested in primary screen**386393358**% of Kit tested**83%84%77%**Avg. Response (Sec.)**348842**St. Dev. (Sec.)**26.474.646.1**Normal Range (Sec.)**20-6020-19010-150**Number selected for verification**896978**Screened phenotype**TSBSBS

The data from the primary screen were organized graphically by average time to recovery or paralysis for each double mutant (Figure [1](#Fig1){ref-type="fig"}). In each case, the resulting data formed a largely normal distribution. Double mutants that deviated significantly from the mean were termed putative enhancers or suppressors and were tested again in a verification screen. The workflow for the genetic screen is depicted in Figure [2](#Fig2){ref-type="fig"}. In the primary screen, 1137 interactions were examined for the three conditional locomotor mutants identifying 117 putative enhancer, suppressor, or synthetic lethal regions. These interactions were examined further in the verification screen.Figure 1**Distribution of phenotypic modifiers identified through a deficiency screen. A-C)** *ATPalpha* mutant animals also bearing individual unique chromosomal deficiencies (Df) were assayed for conditional locomotor function to identify modifiers. The data reveal a largely normal distribution centered around a typical response (blue) for each mutant. Those deviating from the typical response were termed putative enhancers (yellow) or suppressors (red). **A)** *ATPalpha* ^*CJ5*^ *, Df* double mutants and **B)** *ATPalpha* ^*CJ10*^ *, Df* double mutants were assayed for recovery from mechanical stress at adult day 15. **C)** *ATPalpha* ^*DTS1*^ *, Df* double mutants were assayed for time to TS paralysis on adult day 1. **A-C)** The mean response is shown as a dashed green line. +/− 0.5 Std. Dev. are indicated by gray shading.Figure 2**Schematic of the deficiency screen workflow.** Using the Bloomington deficiency kit, 1137 initial interactions were screened using *ATPalpha* ^*CJ5*^, *ATPalpha* ^*CJ10*^, or *ATPalpha* ^*DTS1*^. Putative enhancers and suppressors were selected for verification with a larger sample size. Any verified interacting deficiencies were deemed critical intervals. Once critical intervals were selected a screen for single gene modifiers from within the intervals was performed using available classical mutants and transgenic RNAi strains. If a modifier was found it was retested with other *ATPalpha* alleles to determine whether the interaction was allele-specific.

Verification screen {#Sec4}
-------------------

To mitigate the effect of false positives and confirm that interactions were reproducible before pursuing them further, we performed a verification screen (an independent experiment) with the putative modifiers. We began the verification with 89 *ATPalpha*^*DTS1*^ modifiers (Figure [1](#Fig1){ref-type="fig"}A), 69 *ATPalpha*^*CJ5*^ modifiers (Figure [1](#Fig1){ref-type="fig"}B), and 78 *ATPalpha*^*CJ10*^ modifiers (Figure [1](#Fig1){ref-type="fig"}C). After verification, we took advantage of having two data sets (primary and verification screen) and created a formula to determine the reproducibility of each putative genetic interaction (see [Materials and Methods](#Sec8){ref-type="sec"}). We calculated a reproducibility index (RI) and used it to help us identify the most promising critical intervals. *Dfs* with the highest RIs were prioritized for mapping and secondary screening. This approach yielded 7 putative *ATPalpha*^*DTS1*^ enhancers, 12 suppressors, and five synthetic lethal (enhanced to lethality) combinations (Table [2](#Tab2){ref-type="table"}). The *ATPalpha*^*CJ5*^ screen yielded 13 enhancers, 10 suppressors, and four synthetic lethal combinations (Table [3](#Tab3){ref-type="table"}). The *ATPalpha*^*CJ10*^ primary screen yielded 17 enhancers, 11 suppressors, and one synthetic lethal (Table [4](#Tab4){ref-type="table"}).Table 2**Confirmed** ***ATPalpha*** ^***DTS1***^ **interacting deficienciesDf NameEnh/SupMean +/− SEMTotal NRIHits in regionCoincidence*DTS1**Control**37.8 +/− 2.6**23**-**-**-***Df(3 L)Exel6092Sup76.4 +/− 33.4116.27spz5, FMRFaR, scramb2, alyCJ10Df(2R)ED1725Sup209.8 +/− 57.064.87Df(2R)BSC361Sup87.8 +/− 10.6164.68StjCJ10Df(3 L)BSC33Sup103.9 +/− 34.4144.64Df(3 L)Exel8104Enh27.3 +/− 27.3113.18Df(3R)BSC486Enh17.2 +/− 1.7192.65CJ10Df(2 L)BSC180Sup85.3 +/− 16.5252.13Rbp9CJ10Df(3R)Exel6210Sup151.3 +/− 42.9112.02Df(2R)BSC383Sup129.1 +/− 40.9111.80Df(2 L)BSC278Sup52.3 +/− 14.9251.54Df(3 L)BSC23Enh11.2 +/− 1.1141.53spz5, scramb2, rasp, alyCJ5, CJ10Df(2 L)Exel6005Sup73.9 +/− 23.1191.51Df(3R)BSC650Enh22.1 +/− 2.3131.20Df(2 L)ED1203Enh21.2 +/− 2.1130.92HamCJ5Df(3R)ED2Enh20.0 +/− 2.6250.88Df(2R)ED3728Sup46.3 +/− 8.2150.86Df(1)BSC767Sup138.2 +/− 26.7130.82Df(2R)M60ESup48.1 +/− 5.9250.74Rpl19, painDf(2 L)ED629Enh27.1 +/− 2.9130.49Glutactin, sema-1aDf(3R)ED7665Enh/Leth\--CJ10Df(3R)ED6361Enh/Leth\--Df(3 L)BSC375Enh/Leth\--Df(3R)BSC467Enh/Leth\--CJ10Df(1)BSC708Enh/Leth\--Df(3R)BSC819Enh/Leth\--ATPalphaAll Enh/LethTable 3**Confirmed** ***ATPalpha*** ^***CJ5***^ **interacting deficienciesDf NameEnh/SupMean ± SEMTotal NRIHits in regionCoincidence*CJ5**Control**100.0 +/− 11.4**28**-**-**-***Df(3 L)BSC797Enh240.6 +/− 17.3144.03Df(2 L)BSC214Enh178.7 +/− 22.6152.38Df(3 L)ED4475Enh172.4 +/− 21.4161.97CJ10Df(2 L)BSC781Sup16.2 +/− 4.2251.93Cact, CG5888Df(3R)BSC547Enh165.0 +/− 24.0171.81Sro, Dop1r2, ppk21Df(3 L)M21Enh182.5 +/− 26.2131.80Df(2R)BSC199Enh168.8 +/− 24.2141.63Df(3R)ED5495Enh182.0 +/− 24.0161.62Df(2R)PK1Sup26.9 +/− 8.7201.57PuDf(2 L)Exel6005Enh235.9 +/− 22.6131.55Df(2 L)H20Sup29.2 +/− 6.4251.52Df(2 L)ED1203Sup31.0 +/− 4.8231.52ham, ddcDTS1Df(3 L)BSC23Sup31.6 +/− 8.0171.50rasp, spz5, scramb2, alyDTS1, CJ10Df(2 L)J39Sup23.0 +/− 4.7211.43FKBP59CJ10Df(2R)BSC267Enh144.7 +/− 24.731.38Df(1)BSC825Sup36.7 +/− 7.291.37Df(2 L)BSC213Enh146.3 +/− 46.281.35Df(3 L)Exel6112Enh143.1 +/− 27.7141.35CJ10Df(2 L)ED489Sup41.4 +/− 16.2131.28Ndae1CJ10Df(2 L)ED8142Sup38.9 +/− 7.9241.20Df(2R)BSC429Sup40.1 +/− 16.4161.15Df(2 L)BSC295Enh181.7 +/− 20.2151.09Df(2 L)BSC149Enh107.1 +/− 41.2121.01Df(2 L)BSC233Enh/Leth\--Df(3 L)BSC451Enh/Leth\--Df(3R)BSC469Enh/Leth\--CJ10Df(3R)BSC491Enh/Leth\--Df(3R)BSC819Enh/Leth\--ATPalphaAll Enh/LethTable 4**Confirmed** ***ATPalpha*** ^***CJ10***^ **interacting deficienciesDf NameEnh/SupMean +/− SEMTotal NRIHits in regionCoincidence*CJ10**Control**50.3 +/− 7.1**17**-**-**-***Df(3R)BSC486Enh168.5 +/− 38.864.92DTS1Df(3 L)Exel6112Enh144.6 +/− 15.4184.20CJ5Df(2 L)BSC180Enh151.7 +/− 34.592.93Rbp9DTS1Df(2 L)TW161Enh103.1 +/− 18.2122.89Df(3R)BSC469Enh96.5 +/− 22.9112.59CJ5Df(3R)BSC681Enh98.7 +/− 49.462.32Df(3R)A113Enh92.4 +/− 8.8142.16Df(3R)BSC501Enh91.8 +/− 7.8142.10CG14508Df(3R)ED5495Enh139.6 +/− 34.571.98Df(3 L)Exel6092Enh142.8 +/− 31.5201.85spz5, scramb2, FMRFaR, alyDTS1Df(2R)BSC664Enh60.2 +/− 14.1111.77Df(3R)Exel6196Enh109.1 +/− 28.5111.74Df(3 L)BSC410Enh85.3 +/− 11.1121.54Df(3 L)ED4475Sup8.0 +/− 1.671.48CJ5Df(3 L)BSC23Sup8.0 +/− 3.0181.43rasp, spz5, scramb2, alyDTS1, CJ5Df(2 L)BSC240Enh91.8 +/− 10.9241.43Nckx30C, ppk11, nAChR-alpha6, FKBP59Df(2 L)J39Sup7.9 +/− 2.2251.43FKBP59CJ5Df(2R)BSC361Enh114.0 +/− 26.381.29StjDTS1Df(2R)BSC661Enh78.0 +/− 10.9231.25Df(3R)ED5577Sup14.0 +/− 2.0131.20Df(2 L)ED489Sup12.1 +/− 2.6251.19Ndae1CJ5Df(3 L)ED230Sup13.7 +/− 3.7101.17Df(4)ED6380Sup12.6 +/− 3.6251.14Df(3 L)BSC113Sup14.3 +/− 1.7151.13aayDf(2 L)ED793Sup16.2 +/− 4.1251.09Dyrk2, NimB5, nAChRα5Df(2 L)BSC149Sup16.1 +/− 3.3141.09Df(3R)ED7665Sup16.5 +/− 5.1211.06DTS1Df(3 L)BSC442Enh79.1 +/− 10.4151.02Df(3R)BSC467Enh/Leth\--DTS1Df(3R)BSC819Enh/Leth\--ATPalphaAll Enh/Leth

Single gene identification and testing {#Sec5}
--------------------------------------

After the verification of critical intervals, genes contained within these intervals were selected for testing. Where practical large intervals were narrowed using smaller Dfs. We obtained classical alleles for integral genes from Bloomington, when possible. Each single gene mutant was mated to the *ATPalpha* allele it putatively modified and to *w*^*1118*^. All single gene mutants displayed no BS or TS phenotype as heterozygotes (data not shown). Heterozygous double mutants were again assayed for TS or BS with age matched controls. Significant interacting single gene mutants were also tested with the other *ATPalpha* alleles (Figure [2](#Fig2){ref-type="fig"}). Twenty single gene interactions were found using classical mutants for *ATPalpha*^*DTS1*^ including 19 single gene enhancers and one single gene suppressor. Ten single gene suppressors were found for *ATPalpha*^*CJ5*^. Twenty-four single gene interactions were found with *ATPalpha*^*CJ10*^, all but one of which showed suppression of the mutant phenotypes. In total, 35 single gene interactions were found and, importantly, 14 different genes had effects with more than one *ATPalpha* allele (Table [5](#Tab5){ref-type="table"}).Table 5**Single gene effects confirmed for** ***ATPalpha*** **alleles using classical mutantsCytological regionGeneGenotypePutative function** ^**\#**^**ATPα AlleleNature of interactionSignificance**10B3l(1)10BbE04588Spliceosome component \[[@CR44]\]CJ10Suppressor\*21B1-21B1GalectinDG25505Cell surface protein, galactoside binding \[[@CR45]\]DTS1Enhancer\*\*\*23C9-23C9Rbp9∆1RNA binding \[[@CR46]\]DTS1Enhancer\*23C9-23C9Rbp9∆1\"CJ5Suppressor\*\*\*\*27E-28B1Ndae1MB05294Sodium driven anion exchanger \[[@CR47]\]CJ5Suppressor\*27E-28B1Ndae1MB05294\"DTS1Enhancer\*27E-28B1Ndae1MB05294\"CJ10Suppressor\*29B4-29E4Sema-1aK13702Axon guidance signal and receptor \[[@CR48],[@CR49]\]DTS1Enhancer\*29B4-29E4GltEY22126Cell surface glycoprotein \[[@CR50]\]DTS1Enhancer\*\*\*\*29B4-29E4GltEY22126"CJ10Suppressor\*30C7-30 F2Nckx30CE00401Sodium/Calcium/Potassium exchanger \[[@CR51]\]CJ10Enhancer\*30C7-30 F2Ppk11MB02012Excitatory sodium channel \[[@CR52]\]CJ10Suppressor\*\*\*30C7-30 F2Ppk11MB02012"DTS1Suppressor\*\*\*\*30C7-30 F2Ppk11MB02012"CJ5Suppressor\*\*\*\*30C7-30 F2nAChRα6MB06675ACh receptor subunitCJ10Suppressor\*30C7-30 F2nAChRα6MB06675"CJ5Suppressor\*\*\*\*31C-32EFKBP59EY03538Calcium channel regulator \[[@CR53]\]DTS1Enhancer\*31C-32EFKBP59EY03538\"CJ5Suppressor\*\*\*31C-32EFKBP59EY03538"CJ10Suppressor\*\*\*33A8-33B1Pde1cC04487cAMP/cGMP phosphodiesterase \[[@CR54]\]CJ5Suppressor\*\*\*\*34E4-35B4Dyrk21Serine/Threonine kinase \[[@CR55]\]DTS1Enhancer\*\*\*34E4-35B4Dyrk21\"CJ10Suppressor\*\*\*\*34E4-35B4Nimb5MI01793Bacterial defenseCJ10Suppressor\*\*34E4-35B4nAChRα5MB11647ACh Receptor subunitCJ10Suppressor\*35 F1-36A1Cact7Inhibitor of NF-κB \[[@CR56]\]CJ10Suppressor\*\*\*\*36A8-36 F1Beat-Ia & Fas33/E25Neuronal immunoglobulin-like proteinsCJ5Suppressor\*25 F1-36A1CG5888MB00188Toll 3 like receptorDTS1Enhancer\*\*\*\*25 F1-36A1CG5888MB00188\"CJ5Suppressor\*\*\*\*46 F1-47A9CG42732MB04544Predicted potassium channelDTS1Enhancer\*\*\*\*46 F1-47A9Rpl41/NaCP60EEP348Ribosomal protein; voltage-gated Na^+^ channel \[[@CR57]\]CJ10Suppressor\*46 F1-47A9CG42732MB04544Predicted potassium channelCJ5Suppressor\*\*46 F1-47A9GαoMI00833Heterotrimeric G-protein subunitCJ10Suppressor\*\*\*\*46 F1-47A9CYP49A1 & GαoMB04922Cytochrome P450 & heterotrimeric G-protein subunitDTS1Enhancer\*\*\*\*50B1CG33156MB05931Predicted NAD^+^ kinaseDTS1Enhancer\*\*\*\*57C5-57 F6Pur1GTP cyclohydrolase \[[@CR58]\]CJ5Suppressor\*\*57C5-57 F6Pur1"CJ10Suppressor\*\*\*\*60E6-60E11PainEP2451TRP calcium channel \[[@CR59]\]DTS1Enhancer\*\*60E6-60E11PainEP2451"CJ10Suppressor\*\*\*\*60E6-60E11Rpl19K03704Ribosomal component \[[@CR60]\]DTS1Enhancer\*\*\*\*62E8-63B6Spz5E03444Neurotrophin \[[@CR61],[@CR62]\]DTS1Enhancer\*\*62E8-63B6Spz5E03444"CJ10Suppressor\*\*\*\*62E8-63B6Aly1Regulator of transcription \[[@CR63],[@CR64]\]DTS1Enhancer\*\*\*\*62E8-63B6Raspm47Palmitoyl transferase \[[@CR65],[@CR66]\]DTS1Enhancer\*\*62E8-63B6Raspm47"CJ10Suppressor\*\*\*\*63A3-63A3Scramb2EY01180Predicted phosphatidyl serine scramblaseDTS1Enhancer\*\*\*\*63A3-63A3Scramb2EY01180\"CJ10Suppressor\*\*\*\*67A2-67D13AayS042314Predicted Phosphoserine phosphataseCJ10Suppressor\*\*93B9-93D4Slmb295Ubiquitin ligase \[[@CR67],[@CR68]\]DTS1Enhancer\*\*93B9-93D4Slmb295"CJ10Suppressor\*\*\*\*93B9-93D4Sec152Protein trafficking \[[@CR69],[@CR70]\]DTS1Enhancer\*\*93B9-93D4Sec152"CJ10Suppressor\*\*\*\*93B9-93D4RhoGAP93BEY07136Rac1 GAP \[[@CR71]\]DTS1Enhancer\*98 F10-99B9CG14508G9163Predicted cytochrome CDTS1Enhancer\*\*\*98 F10-99B9CG14508G9163Predicted cytochrome CCJ10Suppressor\*\*\*\*99E1-3RtSro1Ecdysone biosynthetic pathwayCJ10Suppressor\*Many genes had an interaction with more than one allele, although some appear to be allele specific. Double mutants were compared to *ATPalpha* ^*\**^ */+* and heterozygous classical mutant controls. ^\*^p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, ^\*\*\*\*^p \< 0.0001.^\#^Function per flybase.org and / or listed citation.

Gal4 driven RNAi strains result in a loss-of-function phenotype and are well-suited to confirm the hypomorphic effect of a heterozygous *Df*. RNAi knockdown was driven with *da-Gal4* in *ATPalpha* mutant backgrounds. *Daughterless* transcripts are stably expressed throughout the life of a fly and are detectable in every tissue by the FlyAtlas affymetrix array analysis \[[@CR72],[@CR73]\]. We used this driver to ubiquitously express the RNAi constructs and mimic the effect observed with the *Df*. RNAi mediated knockdown of candidate genes was compared to age matched controls lacking the *UAS-RNAi* construct. Twenty-five different genes showed interactions using this method, including 10 genes already identified in the classical mutant screen. Fourteen interactions were identified with *ATPalpha*^*DTS1*^, with nine enhancers and five suppressors. Seventeen interactions, with two enhancers and 15 suppressors, were identified for *ATPalpha*^*CJ5*^. Thirteen interactions, all suppressors, were confirmed with *ATPalpha*^*CJ10*^. In total 15 different genes showed a genetic interaction with two or more *ATPalpha* alleles (Table [6](#Tab6){ref-type="table"}). In total we have identified 50 genes that interact with *ATPalpha*, 25 of which were confirmed to interact with at least two independent alleles.Table 6**Single gene effects confirmed for** ***ATPalpha*** **alleles using RNAiCytological regionGenePutative function** ^**\#**^**ATPα AlleleNature of interactionSignificance**21A1-21B1GalectinGalactoside binding \[[@CR45]\]CJ10Suppressor\*\*21A1-21B1Galectin"CJ5Suppressor\*\*\*22 F4-22 F4CG3528UnknownDTS1Enhancer\*22 F4-22 F4CG3528CJ10Suppressor\*22 F4-22 F4CG3528CJ5Suppressor\*27E-28B1Ndae1Na + driven anion exchanger \[[@CR47]\]CJ5Enhancer\*29B4-29E4GltCell surface glycoprotein \[[@CR50]\]CJ10Suppressor\*30C8-30C9Ppk11Sodium channel \[[@CR52]\]CJ5Suppressor\*\*31C-32EFKBP59Calcium channel regulator \[[@CR53]\]CJ5Suppressor\*\*\*31C-32EFKBP59"DTS1Enhancer\*33A1-33A1Vha100-5ATPase, proton transportDTS1Enhancer\*33A2-33A2EscHistone methyltransferase component \[[@CR74]\]DTS1Enhancer\*\*\*33A2-33A2Esc"CJ10Suppressor\*\*34E4-35B4Dyrk2Serine/Threonine kinase \[[@CR55]\]DTS1Enhancer\*34E4-35B4Dyrk2"CJ5Suppressor\*\*\*37A2-37A4HamTranscription factor \[[@CR75]\]DTS1Suppressor\*37A2-37A4Ham"CJ5Suppressor\*\*37C1-37C1DdcAmino acid decarboxylase \[[@CR76]\]CJ5Suppressor\*\*\*25 F1-36A1CG5888Toll 3 like ReceptorCJ10Suppressor\*\*25 F1-36A1CG5888"CJ5Suppressor\*50C5-50C6StjVoltage-gated calcium channel regulatory subunit \[[@CR77],[@CR78]\]DTS1Enhancer\*\*\*\*50C5-50C6Stj"CJ5Enhancer\*\*51D1-51D1Cyp6a19Cytochrome P450CJ10Suppressor\*62E8-63B6Spz5Neurotrophin \[[@CR61],[@CR62]\]DTS1Suppressor\*\*62E8-63B6Spz5"CJ10Suppressor\*62E8-63B6RaspPalmitoyl transferase \[[@CR65],[@CR66]\]CJ5Suppressor\*\*\*63A3-63A3FMRFaRNeuropeptide receptor \[[@CR79]\]DTS1Enhancer\*\*63A3-63A3FMRFaR"CJ10Suppressor\*\*63A3-63A3FMRFaR"CJ5Suppressor\*\*\*\*64C2-64C5ConHomophilic cell adhesion \[[@CR80]\]DTS1Suppressor\*64C2-64C5Con"CJ5Suppressor\*\*67A2-67D13AayPredicted phosphoserine phosphataseCJ10Suppressor\*67A2-67D13Aay"CJ5Suppressor\*\*67B9-67B9Uch-L526S Proteasome component \[[@CR81]\]DTS1Enhancer\*67D11-67D11Scramb1Phosphatidyl serine scramblaseCJ10Suppressor\*\*99B5-99B6Dop1R2Dopamine 1-like receptor \[[@CR82],[@CR83]\]CJ5Suppressor\*\*\*99B6-99B6Ppk21Sodium channelDTS1Suppressor\*\*99B6-99B6Ppk21"CJ10Suppressor\*100B9-100B9Ppk24Sodium channelDTS1Suppressor\*\*100B9-100B9Ppk24"CJ5Suppressor\*100B9-100B9Ppk24"CJ10Suppressor\*\*100C1-100C1CG11340Predicted chloride channelDTS1Suppressor\*100C1-100C1CG11340"CJ5Suppressor\*\*\*100C1-100C1CG11340"CJ10Suppressor\*Many genes had an interaction with more than one allele, although some appear to be allele specific. RNAi knockdowns were compared with *ATPalpha\*, daGal4/+* controls. ^\*^p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, ^\*\*\*\*^p \< 0.0001.^\#^Function per flybase.org and/or listed citation.

Discussion {#Sec6}
==========

The Na^+^/K^+^ATPase is central to maintaining cytosolic ion homeostasis suggesting that many of the genes identified in our screen would encode proteins that affect cytosolic ion concentrations and, indeed, this was the case (Figure [3](#Fig3){ref-type="fig"}A). Nearly 25% of the genes we identified encode proteins with a known function in ion transport. In our search for single gene modifiers we selected genes known to be expressed in the nervous system. Unsurprisingly, \~50% of our hits are known to cause some neuronal defect when knocked out (Figure [3](#Fig3){ref-type="fig"}B). For example, most of the cell adhesion and paracrine signaling molecules we found, such as *Galectin* (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, Figure [4](#Fig4){ref-type="fig"}), *Glt* (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), and *Sema-1a* (Table [5](#Tab5){ref-type="table"}) were previously known to cause malformed or improperly targeted synapses \[[@CR45],[@CR48]-[@CR50]\]. However, about half of our genes were not previously linked to neuronal function. Additionally, many genes we identified encode proteins implicated in signaling pathways. In particular we found proteins involved in developmental signaling pathways, such as *Wingless* and *Hedgehog* (*rasp* (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}) and *slmb* (Table [5](#Tab5){ref-type="table"})), and neuronal growth and survival pathways (*spz5* (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"})).Figure 3**Distribution of validated genetic modifiers. A**. Protein function of modifiers, as annotated on flybase.org, grouped into major categories. *Stj*, *rasp*, *slmb*, Rpl41/NaCP60E, and *punch* were included in two categories. **B**. Modifier loci categorized according to mutant phenotypes (when available). *FKBP59*, *Cact*, *Scramb1*, and *Stj* were associated with two phenotypic categories.Figure 4**Genetic interaction between** ***Galectin*** **and** ***ATPalpha*** **.** *Galectin; ATPalpha* double mutants and *ATPalpha\**, *Galectin* RNAi flies for each *ATPalpha* mutant were assayed and compared to *ATPalpha\** heterozygous controls. The RNAi knockdown was driven ubiquitously with *daughterless*-Gal4 (daGAL4). The genotypes in each graph are: *ATPalpha\*/+* (green), *Galectin* ^*DG25505*^ */+;ATPalpha\*/+* (red), *daGal4,ATPalpha\*/+* (blue), and *Galectin-RNAi/+;daGal4,ATPalpha\*/+* (orange). *Galectin* mutants significantly enhanced the *ATPalpha* ^*DTS1*^ phenotype while *galectin-RNAi* significantly suppress *ATPalpha* ^*CJ5*^ and *ATPalpha* ^*CJ10*^ phenotypes. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

Spz5 (Figure [5](#Fig5){ref-type="fig"}) is especially interesting because it has recently been identified as a *Drosophila* neurotrophin that signals through a Toll receptor \[[@CR61],[@CR62]\]. Both Slmb and Cact (Table [5](#Tab5){ref-type="table"}) were also identified by our screen and both may function downstream of Spz5. In mammals and flies, Toll signaling activates NF-κB transcription factors, typically through the degradation of an inhibitor of NF-κB (I-κB), such as Cact. Phosphorylated I-κB is targeted for degradation, allowing NF-κB-like transcription factors to translocate to the nucleus. Slmb and its mammalian homolog β-TrCP regulate phospho-I-κB. β-TrCP, and likely Slmb, target an E3 ubiquitin ligase complex to phospho-I-κB and mediate its degradation via ubiquitin proteasome system \[[@CR68]\]. Interestingly, we have also identified Uch-L5 (Table [6](#Tab6){ref-type="table"}) in our screen, a member of the 26S regulatory complex which is likely responsible for the deubiquitylation of proteins as they enter the 26S proteasome \[[@CR81]\].Figure 5**Genetic interaction between** ***Spz5*** **and** ***ATPalpha*** **.** *ATPalpha/Spz5* double mutants and *ATPalpha\**, *Spz5* RNAi flies for each *ATPalpha* mutant were assayed and compared to *ATPalpha\** heterozygous controls. The RNAi knockdown was driven with da-Gal4. The genotypes in each graph are: *ATPalpha\*/+* (green), *Spz5* ^*E03444*^ */ATPalpha\** (red), *daGal4,ATPalpha\*/+* (blue), and *Spz5-RNAi/daGal4,ATPalpha\** (orange). *Spz5* mutants significantly enhanced the *ATPalpha* ^*DTS1*^ phenotype but *Spz5* RNAI significantly suppresses the *ATPalpha* ^*DTS1*^ phenotype. The *ATPalpha* ^*CJ10*^ phenotype is suppressed in both the *Spz5* mutant and RNAi. The *ATPalpha* ^*CJ5*^ phenotype was not significantly affected by loss of *Spz5*. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

Previously published studies of *Slmb*, and *Spz5* show that they play an important role in neural development. Slmb is involved in pruning dendrites and axons during pupation \[[@CR84]\] and Spz5 is a neurotrophic signal and axon guidance cue in the embryonic nervous system \[[@CR61]\]. Interestingly, animals heterozygous for a loss of function allele of either gene displayed no phenotype in neurons \[[@CR61],[@CR85]\]. In contrast, our screen examined heterozygous double mutants and found large effects, suggesting *ATPalpha* mutants are sensitive to otherwise inconsequential changes in neuronal development or another unappreciated function of these proteins. Furthermore, a seemingly insignificant disruption of neuronal survival signals early in development may have dramatic phenotypic effects for *ATPalpha* mutants since heterozygosity of *Slmb*, or *Spz5* suppressed the loss-of-function *ATPalpha* phenotype. Additionally, numerous developmental genes were identified implying that neurodevelopmental changes may profoundly affect Na^+^/K^+^ ATPase function or this is a general and potent mechanism to modulate locomotor function.

Another interesting possibility is that loss-of-function *ATPalpha* mutations are disrupting neuronal development through alterations in NF-κB signaling. It has been shown that sub-inhibitory concentrations of ouabain activate NF-κB via an Na^+^/K^+^ ATPase dependent mechanism in rat kidney cells. The effect is mediated by slow, inositol triphosphate-dependent, calcium oscillations likely caused by shifting electrochemical gradients \[[@CR86]\]. More recently, agrin, a protein involved in synapse formation at NMJs and in the CNS, has been shown to bind to and inhibit the mammalian Na^+^/K^+^ ATPase α3 isoform. Furthermore, agrin seems to bind at the same site as ouabain because a protein fragment can prevent ouabain inhibition of the Na^+^/K^+^ ATPase \[[@CR87]\]. Thus it is possible that agrin exerts its effects through NF-κB. If a similar pathway exists in flies it would likely be constitutively active in our loss-of-function mutants and its dysregulation could cause developmental changes, which might increase seizure susceptibility. This is consistent with our finding that knockdown of proteins required for NF-κB activation suppresses seizures in our loss-of-function mutants. NF-κB activation may be caused by calcium oscillations \[[@CR86]\], making it possible that some of the calcium channels we found also play a role in this pathway. FKBP59 (Figure [6](#Fig6){ref-type="fig"}) is particularly interesting because it inhibits an inositol triphosphate sensitive, non-specific calcium channel, TrpL \[[@CR53]\]. Inhibition of calcium channels would likely be required in calcium oscillations. The preponderance of hits related to the NF-κB pathway suggests a possible role for this pathway in seizure pathogenesis.Figure 6**Genetic interactions between** ***FKBP59*** **and** ***ATPalpha*** **.** *FKBP59; ATPalpha* double mutants and *ATPalpha\*, FKBP59 RNAi* flies were assayed and compared to *ATPalpha\** heterozygous controls. The RNAi knockdown was driven with da-Gal4. The genotypes in each graph are: *ATPalpha\*/+* (green), *FKBP59* ^*E03444*^ */+; ATPalpha\*/+* (red), *daGal4,ATPalpha\*/+* (blue), and *FKBP59-RNAi/+;daGal4,ATPalpha\*/+* (orange). *FKBP59* mutants significantly enhanced the *ATPalpha* ^*DTS1*^ phenotype. The *ATPalpha* ^*CJ5*^ phenotype is suppressed by both the *FKBP59* mutant and RNAi. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

In most cases the *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^ mutant phenotypes were modified in the same direction (enhancement or suppression) and they never had opposite phenotypes in our screen. This is consistent with the finding that both exhibit loss-of-function characteristics. The *ATPalpha*^*DTS1*^ phenotype, however, usually contrasted with the phenotypes of *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^. This is intriguing as *ATPalpha*^*DTS1*^ is a gain-of-function mutation that can be reverted by a second site mutation to give the characteristic *ATPalpha* loss-of-function phenotype \[[@CR23]\]. In accord with this fact the vast majority (\~ 80%) of the single gene interactions with *ATPalpha*^*DTS1*^ modified the loss-of-function alleles in the opposite direction or not at all. Reduction of Ppk11, Ppk21, and Ppk24 function all suppressed the phenotypes of *ATPalpha*^*DTS1*^ and another allele. All three are predicted epithelial sodium channels (DEG/eNaCs) that function in nociception, mechanosensation, gustation and other sensory functions (Reviewed in \[[@CR88]\] and \[[@CR89]\]). Thus, it is possible that altered sensory function may underlie the *ATPalpha*^*DTS1*^ paralysis phenotype and that a reduction in the ability of the double mutant animals to sense the elevated temperature is sufficient to suppress the TS paralysis. This possibility is consistent with the kinetics of recovery after animals are returned to the permissive temperature. This is also intriguing as the locomotor dysfunction resulting in hemiparalysis in FHM patients has been reported to be associated with sensory dysfunction and FHM patients report having prolonged visual auras \[[@CR90]-[@CR92]\].

Conclusions {#Sec7}
===========

FHM, RDP, and AHC are complex human neurological diseases associated with mutations affecting the catalytic alpha subunit of the Na^+^/K^+^ ATPase \[[@CR4]-[@CR6]\]. Currently, there is no cure or effective treatment for these diseases. Using three *Drosophila* strains with different missense mutations in *ATPalpha* we have performed a large-scale deficiency screen to identify novel genes that interact with the gene encoding the Na^+^/K^+^ATPase alpha subunit. In total, we have identified 50 genes that interact with *ATPalpha*, 25 of which were demonstrated to interact with at least two independent alleles. We have also implicated 50 critical intervals/deficiency regions for which we have yet to identify individual genes that interact with *ATPalpha* (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Modifier loci that encode proteins expressed in the adult, especially those that phenotypically suppress *ATPalpha* dysfunction, provide proteins/pathways that could be viable targets for the development of new migraine or anti-epileptic drugs. Additionally, studies of these loci and how they modify ATPalpha dysfunction will help us understand epilepsy, hemiplegia and migraine disease pathogenesis in animals.

Materials and methods {#Sec8}
=====================

*Drosophila* strains {#Sec9}
--------------------

Flies were maintained on standard cornmeal-molasses agar medium at 21-22°C. Chromosomal deficiencies were obtained from the Bloomington Deficiency Kit from the Bloomington Stock Center (order date January 2010). The *Df* Kit we received contained 467 stocks with deletions spanning 97.8% of the *Drosophila* genome. Three Na^+^/K^+^ ATPase alpha subunit mutants were used: *ATPalpha*^*DTS1*^ \[[@CR23]\], *ATPalpha*^*CJ5*^ and *ATPalpha*^*CJ10*^ \[[@CR36]\]. The other *Drosophila* strains used were obtained from the Vienna Drosophila RNAi Center (VDRC) or Bloomington Stock Center.

Locomotor assays {#Sec10}
----------------

F~1~ offspring heterozygous for an *ATPalpha* allele and each individual *Df* were collected upon eclosion (day 0) and aged at 25°C on cornmeal-molasses medium. Temperature sensitivity (TS) was assayed on day 1 and bang sensitivity (BS) was assayed on day 15 as described previously \[[@CR23]\]. Aged flies were moved to an empty vial in groups of 5 or fewer using an aspirator. For TS, the vial was submerged in a water bath at 38°C such that the flies were restricted to space in the vial below the waterline. A timer was started when the vial was submerged and time to paralysis was recorded for each fly. For BS, the vial was mechanically shaken using a standard lab Vortex Genie 2 (Daigger, IL) on the highest setting for 20 seconds. Time to recovery for each fly was recorded. Both conditional locomotor assays were stopped after 300 seconds.

*Df* Interaction screen {#Sec11}
-----------------------

### Initial Screens {#Sec12}

Males with autosomal deficiencies were mated to *ATPalpha*^*DTS1*^, *ATPalpha*^*CJ5*^, and *ATPalpha*^*CJ10*^ virgin females, and X-linked deficiency virgin females were mated with *ATPalpha*^*DTS1*^, *ATPalpha*^*CJ5*^, and *ATPalpha*^*CJ10*^ males. F~1~ progeny representing a total of 386 deficiency interactions were tested with *ATPalpha*^*DTS1*^ animals (83% of *Df* kit), 393 were tested with *ATPalpha*^*CJ5*^ (84% of *Df* kit), and 358 were tested with *ATPalpha*^*CJ10*^ animals (77% of *Df* kit). Each of the 467 *Dfs* we received was tested with at least one *ATPalpha* allele, the vast majority were tested with multiple alleles and \>55% were tested with all three alleles. Assays were performed as described above.

### Verification screen {#Sec13}

Putative modifier *Df* strains identified in the initial screen were retested in an independent experiment to verify the findings and reduce the rate of false positives. In selecting *Df* stains to test again, we favored *Dfs* that suppressed *ATPalpha* mutant phenotypes and/or interacted with more than one *ATPalpha* allele. During the verification screen all three *ATPalpha* alleles were investigated.

Single gene identification {#Sec14}
--------------------------

We developed an analysis called the Reproducibility Index (RI) in order to guide our search for single gene modifiers of the *ATPalpha* alleles. The goal of this index was to rank the most promising *Df* intervals based on the magnitude and reproducibility with which they modified an *ATPalpha* allele phenotype. To this end, we first calculated the number of standard deviations of the *Df, ATPalpha\** double mutant mean from the total mean of the primary screen of each *ATPalpha mutant* using:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}
                            $$ Num.Std.Dev.\left(\#SD\right)=\frac{Mea{n}_{total}-Mea{n}_{Df}}{StdDe{v}_{total}} $$
                        \end{document}$$

where StdDev~total~ is the standard deviation of all deficiencies in the primary screen, Mean~total~ is the mean of all deficiencies in the primary screen, and Mean~Df~ is the mean response of a *Df/ATPalpha* double mutant. Num.Std.Dev (\#SD) was calculated for the mean response of a *Df* double mutant in the primary (\#SD~prim~) and verification (\#SD~veri~) screen. We reasoned that these values provide a normalized metric of how much a *Df* modified an *ATPalpha* phenotype in each trial. We used these values to calculate the RI:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}
                            $$ RI=\left|\operatorname{}S{D}_{prim}+\#S{D}_{veri}\right|-AV/2 $$
                        \end{document}$$

where$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \usepackage{amsfonts} 
                \usepackage{amssymb} 
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                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}
                            $$ Absolute\  Varience(AV)=\left|\#S{D}_{prim}-\#S{D}_{veri}\right| $$
                        \end{document}$$

The RI increases for *Dfs* that were further from the total mean and decreases for *Dfs* that varied more across the two trials. Thus, a high RI suggests that a region is more likely to contain a gene that interacts with and modifies an *ATPalpha* allele in a reproducible manner. In some intervals we were able to use small *Dfs* to narrow the interval further. We, again, prioritized strongly suppressing intervals over enhancing intervals and intervals that interacted with multiple alleles. Single genes were selected from critical intervals using the G-Browse feature (an annotated genome) of flybase.org. In some very small intervals all genes in the region were tested. In large intervals we necessarily focused on genes with described expression within the nervous and or muscular systems, introducing a noted bias. Many of the alleles chosen were P-element or classical mutations reported to knockout the genes of interest. The stocks of interest were ordered from the Bloomington Stock Center.

RNAi analysis {#Sec15}
-------------

When classical mutants were unavailable for certain loci or to confirm an interaction found using a classical mutant, RNAi analysis was used to examine the gene in question. RNAi stocks were ordered from the VDRC. The RNAi transgenes were driven using *daughterless* Gal4 strains (*daGal4*) in each *ATPalpha* mutant background. RNAi male flies were mated to ATP*alpha*, *daGal4* virgin females. Progeny were raised at 25°C, and TS and BS tests were performed as described previously.

Data collection and statistics {#Sec16}
------------------------------

Data were collected and organized using Microsoft Excel (Redmond, WA). Data were analyzed in GraphPad Prism 5 (San Diego, CA). We used ANOVA to compare the *ATPalpha* mutant heterozygotes, the classical mutant heterozygotes, and flies heterozygous for both alleles. Tukey's multiple comparison test was performed to determine if the double mutants were significantly different from the *ATPalpha* mutant heterozygote and the classical mutant heterozygote. Adjusted p-values are reported in Table [5](#Tab5){ref-type="table"}. The effect of RNAi transgenes was analyzed using a Student's *t-test* to determine if single gene knockdowns significantly modified the phenotype of *ATPalpha\*, daGal4* controls. Significant interactions are reported in Table [6](#Tab6){ref-type="table"}.

Additional file {#Sec17}
===============

Additional file 1:**Data from the primary and verification** ***Df*** **screens.**
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